

Neurotech

6 April 2021

Appointment of Krista Bates as Non-Executive Director

Neurotech International Limited (ASX: NTI) ("Neurotech" or "the Company") is pleased to advise that Krista Bates has been appointed as non-executive director, effective from 5 April 2021.

Ms Bates is an experienced non-executive and executive director of listed companies (Australian Stock Exchange and London Stock Exchange) and various private companies in multiple jurisdictions. She is commercially experienced, particularly talented in turnarounds, structuring, risk mitigation and strategic roll-out of commercial initiatives. She has an exceptional legal background with over 20 years' experience in the legal market, with extensive experience working in emerging markets in both a commercial and legal capacity.

Ms Bates is currently a Non-executive Director of AusCann Holdings (ASX:AC8) and Australia-Africa Minerals & Energy Group. She is also a Corporate Partner at Lavan law firm, where she is Head of Mining & Resources Group and Head of Medical Cannabis Group. Formerly, she has held both Executive and Non-executive Directorship roles at Credit Intelligence (ASX:CI1) and Fastjet, London, Nairobi, Harare and Dar es Salaam (LSE:FJET), and has held Corporate Partner roles at Anjarwalla & Khanna (Nairobi, Kenya) and Clyde & Co (London and Dar es Salaam, Tanzania).

Commenting on Ms Bates appointment, Neurotech International Limited's Chairman, Mr Brian Leedman said, "We are fortunate to have a new Director appointment of Krista's calibre as the company begins a world first human trial assessing full spectrum medicinal cannabis plant with less than 0.3% THC for children with Autism".

As part of her appointment, the Company has agreed to seek shareholder approval for a grant of 500,000 options to Ms Bates, with a 9c exercise price and expiring on the same date as the options proposed to be issued to Merchant Capital Pty Ltd as a fee for capital raising services (in any case, the expiry date is expected to be on or around 7 May 2023).

Authority

This announcement has been authorised for release by the Board of the Company.

Further Information

Brian Leedman
Chairman
+61 41 228 1780

Winton Willesee
Non-Executive Director
winton@azc.com.au
+61 410 667 844

Neurotech International Ltd
ABN 73 610 205 402
Suite 5 CPC, 145 Stirling Highway
Nedlands, Western Australia 6009
www.neurotechinternational.com

About Neurotech

Neurotech International Limited is a medical device and solutions company conducting clinical studies to assess the neuro-protective, anti-inflammatory and neuro-modulatory activities of our proprietary NTI/Dolce cannabis strains. Neurotech is also commercialising Mente, the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity. For more information about Neurotech and Mente Autism please visit <http://www.neurotechinternational.com>